国药集团一致药业股份有限公司2015年年度报告摘要 Stock Code: 000028/200028 Notice No.:
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
Summary of Annual Report 2015
I. Important Notice
The summary is abstract from full-text of annual report, for more details of operating results, financial condition and future development plan of the Company; investors should found in the full-text of annual report that published on media appointed by CSRC.
Objection statement of directors, supervisors and senior executives
||||
|-|-|-|
|Name|Position|Content and reason|

Statement
Other directors attending the Meeting for annual report deliberation except for the followed
|||||
|-|-|-|-|
|Name of director absent|Title for absent director|Reasons for absent|Attorney|

Prompt of non-standard audit opinion
□ Applicable√ Not applicable
Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting period
√Applicable□Not applicable
Whether has capitalizing of common reserves carried out
□Yes√ No
The profit distribution plan that deliberated and approved by the Board is: based on total stock issued 362, 631, 943 shares, distributed 3.00 Yuan (tax included) bonus in cash for every 10-share hold by all shareholders, 0 shares bonus issued (tax included) and no capitalizing of common reserves carried out.
Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period
□ Applicable√ Not applicable
Company Profile
||||||
|-|-|-|-|-|
|Short form of the stock|Sinopharm Accord, Accord B|Stock code||000028、200028|
|Stock exchange for listing|Shenzhen Stock Exchange||||
|Person/Way to contact|Secretary of the Board||Rep. of security affairs||
|Name|Chen Changbing||||
||Accord Pharm. Bldg., No. 15, Ba Gua SiRoad, Futian District, Shenzhen, GuangdongProvince||||
|Office add.|||||
|Fax.|+(86)755 25195435||||
|Tel.|+(86)755 25875195||||
||0028@szaccord.com.cn；gyyz0028@sinopharm.com||||
|E-mail|||||

II. Main business or product introduction in the reporting period
The main business of China National Accord Medicines includes pharmaceutical distribution and pharmaceutical industry; the company adheres to the joint
development of technical research and development, industrial manufacturing and
marketing and trade, and commits to become a provider for pharmaceutical and
国药集团一致药业股份有限公司2015年年度报告摘要 healthcare products and services with international competitiveness.
(I) In the pharmaceutical distribution field, the company continues to integrate the distribution and logistics business, deeply penetrates into the end markets, improves the multistep distribution network, creates intelligent supply chain, and devotes to become a provider for pharmaceutical and healthcare products and services with the strongest influence, the highest share, the most complete variety, the best service, and the fastest delivery in south district of China.
(II) In the pharmaceutical industry field, the company continues to integrate the research& development and marketing and take the technological innovation as a guide so as to become a provider for pharmaceutical and healthcare products and services with quality leadership, core competitiveness, transverse diversification, complete lengthways industry chain and brand influence in the domestic and international markets
III. Main accounting data and financial indexes
1. Main accounting data and financial indexes for recently three years
Whether it has retroactive adjustment or re-statement on previous accounting data for accounting policy changed and accounting error correction or not
□Yes√ No
In RMB
||||||
|-|-|-|-|-|
||||Changes over last||
||2015|2014||2013|
||||year||
|Operating income|25,993,139,277.84|23,954,331,028.05|8.51%|21,199,466,399.21|
|Net profit attributable to|761,312,261.06|652,497,176.03|||
|shareholders of the listed|||16.68%|520,488,198.80|
|company|||||
|Net profit attributable to|||||
|shareholders of the listed|||||
||715,212,681.54|611,245,652.69|17.01%|505,828,794.23|
|company after deducting|||||
|non-recurring gains and losses|||||
|Net cash flow arising from|1,047,979,102.98|-796,697,032.43|||
||||231.54%|465,028,099.83|
|operating activities|||||
|Basic earnings per share|2.10|1.90|||
||||10.53%|1.81|
|(RMB/Share)|||||
|Diluted earnings per share|2.10|1.90|||
||||10.53%|1.81|
|(RMB/Share)|||||
|Weighted average ROE|14.94%|16.41%|-1.47%|26.00%|
||||Changes over end of||
||End of 2015|End of 2014||End of 2013|
||||last year||
|Total assets|13,218,349,735.31|12,828,941,540.90|3.04%|11,057,896,941.31|
|Net assets attributable to|5,453,393,694.55|4,764,607,822.09|||
||||14.46%|2,244,757,658.03|
|shareholder of listed company|||||

2. Quarterly main financial index
In RMB
国药集团一致药业股份有限公司2015年年度报告摘要
||||||
|-|-|-|-|-|
||First quarter|Second quarter|Third quarter|Fourth quarter|
|Operating income|6,261,714,700.23|6,552,088,466.54|6,866,003,376.77|6,313,332,734.30|
|Net profit attributable to|197,026,237.82|190,293,014.51|186,753,078.44|187,239,930.29|
|shareholders of the listed|||||
|company|||||
|Net profit attributable to|192,315,542.07|181,343,611.72|183,019,662.66|158,533,865.09|
|shareholders of the listed|||||
|company after deducting|||||
|non-recurring gains and losses|||||
|Net cash flow arising from|182,179,606.70|266,059,972.13|-40,080,428.91|639,819,953.06|
|operating activities|||||

Whether there are significant differences between the above-mentioned financial index or its total number and the relevant financial index disclosed in thecompany’s quarterly report and semi-annual report
□Yes√ No
IV. Shares and shareholders
1. Particulars about common stock shareholders, preference shareholders with voting rights recovered and top ten shareholders
In Share
||||||||||||
|-|-|-|-|-|-|-|-|-|-|-|
|||||||||Total preference|||
|||Total common||||Total preference|||||
|Total commonstock||||||||shareholders with|||
|||stock||||shareholders|||||
|||||||||voting rights|||
|||shareholders at||||with voting|||||
|shareholders in|14,861|||14,861|||0|recovered at end of||0|
|||end of last month||||rights recovered|||||
|reportingperiod-end||||||||last month before|||
|||before annual||||at end of|||||
|||||||||annual report|||
|||report disclosed||||reporting period|||||
|||||||||disclosed|||
|Top ten shareholders|||||||||||
||||||Amount of||||Number of shares||
|Full name of|Nature of||Proportion of||||||||
|||||||Amount of restricted shares held|||pledged/frozen||
|Shareholders|shareholder||shares held||shares held||||||
||||||||||State of share|Amount|
|SinopharmHolding Co.,Ltd.|State-ownedCorporation||51.00%||184,942,291|74,482,543|||||
|NationalCouncil forSocial SecurityFund-116|Domesticnonstate-ownedCorporation||2.29%||8,300,000||||||
||Domesticnonstate-ownedCorporation||2.12%||7,704,972||||||
|China Securities|||||||||||
|Finance Co.,|||||||||||
|Ltd.|||||||||||
|NationalCouncil forSocial SecurityFund-106|Domesticnonstate-ownedCorporation||2.01%||7,298,555||||||
|HTHK/CMGFSGUFP-CMGFIRST STATECHINAGROWTH FD|ForeignCorporation||1.94%||7,032,720||||||
|VALUEPARTNERSCLASSICFUND|ForeignCorporation||1.58%||5,737,088||||||
|CITIC|Domesticnon||1.38%||5,009,037||||||
|Securities Co.,|||||||||||

国药集团一致药业股份有限公司2015年年度报告摘要
|||||
|-|-|-|-|
||state-ownedCorporation|||
|New China LifeInsurance Co.,Ltd. – Bonus –Individualbonuses --018L-FH002Shen|Domesticnonstate-ownedCorporation|1.16%|4,199,772|
|Central Huijin|State-ownedCorporation|1.05%|3,804,400|
|Investment Ltd.||||
|China LifeInsurance Co.,Ltd. – tradition–generalinsuranceproducts-005L-CT001Shen|Domesticnonstate-ownedCorporation|1.03%|3,750,090|
|Explanation on associated||It is unknown that there exists no associated relationship or belongs to the consistent actionist||
|relationship among the||among the other tradable shareholders regulated by the Management Measure of Information||
|aforesaid shareholders||Disclosure on Change of Shareholding for Listed Companies.||

2. Total preferred stock shareholders of the Company and shares held by top ten shareholders with preferred stock held
□ Applicable√ Not applicable
The Company had no shareholders with preferred stock held in the reporting.
国药集团一致药业股份有限公司2015年年度报告摘要 3. Property right and controlling relationships between the actual controllers of the Company and the Company is as follows:
The State-owned Assets Supervision& Administration Commission of the State Council
100%
National Council for Social Security Fund&public China National Pharmaceutical
Shanghai Fosun Pharmaceutical shareholder
Group Corporation
(Group) Co., Ltd.
49% 51% 43.11%
Sinopharm Industry
Investment Co., Ltd.
0.10%
56.79%
Sinopharm Holding Co., Ltd.
51%
China National Accord Medicines Corporation Ltd.
V. Discussion and analysis by the Management Team
1. Introduction of operation in the reporting period
2015 is the last year of "the
12th
Five-Year Plan". In the past year, the company has always faced the challenges beyond imagination and changeable environment, the pressure of macro economy downturn was increasing, the financial field was unordered and turbulent, and the changes of various policies including clinical drug verification, new versions of GMP / pharmacopeia, unannounced inspection, electronic supervision code, and decrease of bid price make us have no time for them. In face of the harsh environment and unfavorable situation, the company has ensured the performance growth, the managers at all levels and staff have assumed
国药集团一致药业股份有限公司2015年年度报告摘要 responsibilities and responded actively, thecompany’s annual sales has exceeded 30 billion yuan in the joint efforts of all staff, the net profit has continued a steady and rapid growth, and the cash flow has got the best level. At the same time, in thecompany’s published major asset restructuring programs, the company has been determined to engage in the distribution business in Guangdong and Guangxi, create the unique national retail platform of China National Pharmaceutical Group, and participate in pharmaceutical industry. All these depend on the support of shareholders, the endeavor of team, and the hard work of all staff; our market position has established the company's scale, and our efforts have supported our values.
In 2015, the Company realized operating income of RMB 25.993 billion, representing a year-on-year increase of8.51%; net profit attributable to shareholders of listed company of RMB 761 million, representing a year-on-year increase of16.68%. The Company has continued to keep growth.
As for distribution segment, operating income was RMB 24.325 billion, representing a year-on-year increase of9.10%; net profit of RMB 439 million, representing a year-on-year increase of24.16%.
As for pharmaceutical segment, operating income was RMB 1.677 billion, representing a year-on-year decrease of0.30%; net profit of RMB 254 million, representing a year-on-year increase of12.51%.
The major works done throughout the year:
1. Innovate management ideas, promote quality and efficiency
2. Optimize industry structure, and product mix becomes more reasonable 3. Speed up the distribution network sink to form complete network coverage 4. New distribution business has significantly enhanced and formed new scale contributions
5. Promote the construction of industrial base and expand the space for industrial development
6. Establish an international brand, and strengthen the competitive advantages of domestic species
7. Focus on the strategy of large variety, and drive the industrial transformation 8. Major asset restructuring of the Company
More details can be seen in the full text of annual report of “I-Introduction” in “VI-Discussion and Analysis by the Management Team”
2. Whether the main business had major change in the reporting period
□ Yes√ No
3. About the industries, products, or regions accounting for over10% of thecompany’s operating income or operating profit
□ Applicable√ Not applicable
4. Whether the characteristics of management seasonal or cyclical need special attention
□ Yes√ No
国药集团一致药业股份有限公司2015年年度报告摘要 5. In the reporting period, note of major changes in operating income, operating cost, total net profit attributable to common stock shareholders of listed company or composing the previous reporting period□ Applicable√ Not applicable
6. Particular about suspended and delisting
□ Applicable√ Not applicable
VI. Relevant items involving financial report
1. Particulars about the changes in aspect of accounting policy, estimates and calculation method compared with the financial report of last year
□ Applicable√ Not applicable
No particulars about the changes in aspect of accounting policy, estimates or calculation method in Period.
2. Major accounting errors within reporting period that needs retrospective restatement
□ Applicable√ Not applicable
No major accounting errors within reporting period that needs retrospective restatement for the Company in the period.
3. Compare with lastyear’s financial report; explain changes in consolidationstatement’s scope
√Applicable□Not applicable
Enterprise newly established: Sinopharm Holding Guangzhou Medical Management Co., Ltd.
4. Explanation on “Qualified Opinion” from the Certified Public Accountants in the report period by the Board of Directors and Supervisory Committee
□ Applicable√ Not applicable